Abbott

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

Alere said its would-be acquirer has no grounds for seeking termination, but Abbott cited adverse material events as a basis for ending the deal.

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

The CDC noted that if the test yields a negative RNA NAT result, clinicians should then analyze patient serum using an IgM antibody test.

The ratings agency also assigned a Negative Rating Watch to the firm's notes offering, noting it will resolve this notation as more details of the offering become available.

Abbott said that a lawsuit it filed Thursday tries to obtain important information from Alere before its acquisition is completed.

The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.

Shareholder approval follows China's avowal that it will not block the deal and Abbott's CEO confirming his faith in Alere's business. 

CEO Miles White said that he still believes that Alere is a good strategic fit for Abbott, and the firm is pursuing all of the necessary regulatory approvals for the deal.